"Novo Sees Generic Ozempic Delayed in China Until Next Year", SWI swissinfo , 6 May 2026, archived from the original on 29 May 2026 "Drugmaker seeks approval for China's first biosimilar Ozempic"
GLP-1 Weight Loss Medications: The Good, the Bad, and the Ugly And What Theyre Really Doing to Your Muscle, Metabolism, and Long-Term Results December 19, 2025 GLP-1 Weight Loss Medications: The Good, the Bad, and the Ugly And What Theyre Really Doing to Your Muscle, Metabolism, and Long-Term Results Photo Credit: Shutterstock GLP-1 weight loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have exploded in popularity over the last few years
And we believe in combination with the rest of the portfolio, that will be included and available to patients over a long period of time
BMI Standards (Commonly Used Criteria): For weight management purposes, GLP-1 medications are typically considered for individuals with: BMI of 30 or higher (obesity), OR BMI of 27 or higher with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, etc.) These are general clinical guidelines used in FDA-approved product labeling and may inform provider decisions